These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22338086)

  • 1. Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse.
    Tanabe K; Lanaspa MA; Kitagawa W; Rivard CJ; Miyazaki M; Klawitter J; Schreiner GF; Saleem MA; Mathieson PW; Makino H; Johnson RJ; Nakagawa T
    Am J Physiol Renal Physiol; 2012 May; 302(9):F1151-60. PubMed ID: 22338086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
    Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
    Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats.
    Serizawa K; Yogo K; Aizawa K; Tashiro Y; Ishizuka N
    Cardiovasc Diabetol; 2011 Nov; 10():105. PubMed ID: 22107602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. eNOS deficiency predisposes podocytes to injury in diabetes.
    Yuen DA; Stead BE; Zhang Y; White KE; Kabir MG; Thai K; Advani SL; Connelly KA; Takano T; Zhu L; Cox AJ; Kelly DJ; Gibson IW; Takahashi T; Harris RC; Advani A
    J Am Soc Nephrol; 2012 Nov; 23(11):1810-23. PubMed ID: 22997257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arginase inhibition mediates renal tissue protection in diabetic nephropathy by a nitric oxide synthase 3-dependent mechanism.
    You H; Gao T; Cooper TK; Morris SM; Awad AS
    Kidney Int; 2013 Dec; 84(6):1189-97. PubMed ID: 23760286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists.
    Kosugi T; Heinig M; Nakayama T; Matsuo S; Nakagawa T
    Am J Pathol; 2010 Feb; 176(2):619-29. PubMed ID: 20042665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice.
    Kanetsuna Y; Takahashi K; Nagata M; Gannon MA; Breyer MD; Harris RC; Takahashi T
    Am J Pathol; 2007 May; 170(5):1473-84. PubMed ID: 17456755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Puerarin attenuates diabetic kidney injury through the suppression of NOX4 expression in podocytes.
    Li X; Cai W; Lee K; Liu B; Deng Y; Chen Y; Zhang X; He JC; Zhong Y
    Sci Rep; 2017 Nov; 7(1):14603. PubMed ID: 29097815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice.
    Kosugi T; Heinig M; Nakayama T; Connor T; Yuzawa Y; Li Q; Hauswirth WW; Grant MB; Croker BP; Campbell-Thompson M; Zhang L; Atkinson MA; Segal MS; Nakagawa T
    Am J Pathol; 2009 Apr; 174(4):1221-9. PubMed ID: 19246639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelial nitric oxide synthase.
    Nakagawa T; Johnson RJ
    Contrib Nephrol; 2011; 170():93-101. PubMed ID: 21659762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined inhibition of CCR2 and ACE provides added protection against progression of diabetic nephropathy in
    Tesch GH; Pullen N; Jesson MI; Schlerman FJ; Nikolic-Paterson DJ
    Am J Physiol Renal Physiol; 2019 Dec; 317(6):F1439-F1449. PubMed ID: 31566438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low nitric oxide bioavailability upregulates renal heparin binding EGF-like growth factor expression.
    Miyazawa T; Zeng F; Wang S; Fan X; Cheng H; Yang H; Bian A; Fogo AB; Harris RC
    Kidney Int; 2013 Dec; 84(6):1176-88. PubMed ID: 23760291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy.
    Jha JC; Thallas-Bonke V; Banal C; Gray SP; Chow BS; Ramm G; Quaggin SE; Cooper ME; Schmidt HH; Jandeleit-Dahm KA
    Diabetologia; 2016 Feb; 59(2):379-89. PubMed ID: 26508318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetylcysteine protects against diabetic nephropathy through control of oxidative and nitrosative stress by recovery of nitric oxide in rats.
    Nogueira GB; Punaro GR; Oliveira CS; Maciel FR; Fernandes TO; Lima DY; Rodrigues AM; Mouro MG; Araujo SRR; Higa EMS
    Nitric Oxide; 2018 Aug; 78():22-31. PubMed ID: 29778909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective phosphodiesterase-5 (PDE-5) inhibitor vardenafil ameliorates renal damage in type 1 diabetic rats by restoring cyclic 3',5' guanosine monophosphate (cGMP) level in podocytes.
    Fang L; Radovits T; Szabó G; Mózes MM; Rosivall L; Kökény G
    Nephrol Dial Transplant; 2013 Jul; 28(7):1751-61. PubMed ID: 23203993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diabetic endothelial nitric oxide synthase knockout mice develop advanced diabetic nephropathy.
    Nakagawa T; Sato W; Glushakova O; Heinig M; Clarke T; Campbell-Thompson M; Yuzawa Y; Atkinson MA; Johnson RJ; Croker B
    J Am Soc Nephrol; 2007 Feb; 18(2):539-50. PubMed ID: 17202420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of diabetic nephropathy between male and female eNOS
    Ma Y; Li W; Yazdizadeh Shotorbani P; Dubansky BH; Huang L; Chaudhari S; Wu P; Wang LA; Ryou MG; Zhou Z; Ma R
    Am J Physiol Renal Physiol; 2019 May; 316(5):F889-F897. PubMed ID: 30810354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophages directly mediate diabetic renal injury.
    You H; Gao T; Cooper TK; Brian Reeves W; Awad AS
    Am J Physiol Renal Physiol; 2013 Dec; 305(12):F1719-27. PubMed ID: 24173355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy.
    Lin M; Yiu WH; Li RX; Wu HJ; Wong DW; Chan LY; Leung JC; Lai KN; Tang SC
    Kidney Int; 2013 May; 83(5):887-900. PubMed ID: 23423259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Podocyte-specific VEGF-a gain of function induces nodular glomerulosclerosis in eNOS null mice.
    Veron D; Aggarwal PK; Velazquez H; Kashgarian M; Moeckel G; Tufro A
    J Am Soc Nephrol; 2014 Aug; 25(8):1814-24. PubMed ID: 24578128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.